REGULATORY

MHLW Urges Prioritized Delivery of Drugs under Shipment Control to Ishikawa

By Takashi Ebisawa January 22, 2024

The Ministry of Health, Labor and Welfare (MHLW) has issued a notice to relevant pharma groups asking that drugs currently under shipment restrictions be supplied with priority to Ishikawa Prefecture affected by the New Year’s earthquake. However, it stopped short of requesting the outright lifting of such curbs there.

The move came in response to a plea made by Keiji Nakamori, president of the Ishikawa Pharmaceutical Association, who met directly with Health Minister Keizo Takemi during his visit to the Ishikawa capital of Kanazawa on January 18.

During the meeting, Mr Nakamori explained that medicines were lacking in disaster-struck areas and sought emergency measures such as lifting shipment controls in Ishikawa to enable the securing of necessary drugs. The minister responded to this plea by instructing MHLW officials to appropriately take care of this matter.

On receiving this instruction, the MHLW issued a notice later in the day to the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ), the Federation of Japan Pharmaceutical Wholesalers Association (JPWA), and an association of drug distributors in Ishikawa. In the notice, the ministry stated that stakeholders in the quake-hit areas have voiced concerns over the stable supplies of ethical medicines and called on prioritized deliveries of shipment-restricted drugs in order to meet the demands of those regions.

The distributor association of Ishikawa and the JPWA had made a similar request to the FPMAJ on January 9, asking for prioritized drug supplies to the Hokuriku region in central Japan, including Ishikawa. The latest MHLW notification is intended to ensure that this request comes through.

Although the Ishikawa Pharmaceutical Association had sought the lifting of shipment restrictions, the MHLW’s notice was confined to asking the industry to prioritize supplies of the relevant products.

The MHLW said to Jiho on January 19, “As shipment controls are determined by respective makers according to their shipment volume and demand, it is difficult for the government to reverse this across the board.” The ministry asked for understanding, saying that the wording in the notice was the most it could use within its power.

Still, the MHLW expects that the notice will bring about actions almost equivalent to the lifting of curbed shipments, with the next focus to be on how manufacturers and wholesalers will respond to this call.

Related Article

REGULATORY

By Shunsuke Tani

PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…

By Takashi Ebisawa

Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…

By Koji Shimomura

Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…

Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…

By Takashi Ebisawa

Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…